Interleukin (IL)-6 modulates transforming growth factor-b expression in skin and dermal fibroblasts from IL-6-deficient mice

British Journal of Dermatology

Volumn 161, Issue 2, 2009, Pages 237-248

  Luckett Chastain, L R ^a   Gallucci, R M ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Collagen; Fibroblast; IL 6; Inflammation; Skin; TGF b

Indexed keywords

INTERLEUKIN 6; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ANIMAL; ARTICLE; C57BL MOUSE; FIBROBLAST; GENETICS; IMMUNOHISTOCHEMISTRY; INJURY; METABOLISM; MOUSE; MOUSE MUTANT; NEWBORN; PATHOLOGY; PHYSIOLOGY; SKIN;

ANIMALS; ANIMALS, NEWBORN; FIBROBLASTS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 73349121322     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09215.x     Document Type: Article

References (85)

1. Bandyopadhyay P. Novel therapies in diabetes mellitus. Drug News Perspect 2006; 19:499-507.
2. Menke A, Muntner P, Wildman RP et al. Measures of adiposity and cardiovascular disease risk factors. Obesity (Silver Spring) 2007; 15:785-95.
3. Bello YM, Phillips TJ. Recent advances in wound healing. J Am Med Assoc 2000; 283:716-18.
4. Dennler S, Goumans MJ, ten Dijke P. Transforming growth factor beta signal transduction. J Leukoc Biol 2002; 71:731-40.
5. Verrecchia F, Mauviel A. Control of connective tissue gene expression by TGF beta: role of Smad proteins in fibrosis. Curr Rheumatol Rep 2002; 4:143-9.
6. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425:577-84.
7. ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004; 29:265-73.
8. Miyazawa K, Shinozaki M, Hara T et al. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 2002; 7:1191-204.
9. Crowe MJ, Doetschman T, Greenhalgh DG. Delayed wound healing in immunodeficient TGF-beta 1 knockout mice. J Invest Dermatol 2000; 115:3-11.
10. Vaughan MB, Howard EW, Tomasek JJ. Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res 2000; 257:180-9.
11. Tredget EB, Demare J, Chandran G et al. Transforming growth factor-beta and its effect on reepithelialization of partial-thickness ear wounds in transgenic mice. Wound Repair Regen 2005; 13:61-7.
12. Laplante AF, Germain L, Auger FA et al. Mechanisms of wound reepithelialization: hints from a tissue-engineered reconstructed skin to long-standing questions. FASEB J 2001; 15:2377-89.
13. Levine JH, Moses HL, Gold LI et al. Spatial and temporal patterns of immunoreactive transforming growth factor beta 1, beta 2, and beta 3 during excisional wound repair. Am J Pathol 1993; 143:368-80.
14. Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002; 118:211-15.
15. Annoni G, Weiner FR, Zern MA. Increased transforming growth factor-beta 1 gene expression in human liver disease. J Hepatol 1992; 14:259-64.
16. Saunier EF, Akhurst RJ. TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 2006; 6:565-78.
17. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342:1350-8.
18. Gacka M, Adamiec J. [The role of transforming growth factor-beta in the pathogenesis of diabetic retinopathy]. Przegl Lek 2006; 63:296-8 [In Polish].
19. Sehgal PB. Interleukin-6: molecular pathophysiology. J Invest Dermatol 1990; 94:S2-6.
20. Paquet P, Pierard GE. Interleukin-6 and the skin. Int Arch Allergy Immunol 1996; 109:308-17.
21. Grossman RM, Krueger J, Yourish D et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989; 86:6367-71.
22. Koch AE, Kronfeld-Harrington LB, Szekanecz Z et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 1993; 61:239-46.
23. Fugger L, Morling N, Bendtzen K et al. IL-6 gene polymorphism in rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, systemic lupus erythematosus, and in healthy Danes. J Immunogenet 1989; 16:461-5.
24. Sawamura D, Meng X, Ina S et al. Induction of keratinocyte proliferation and lymphocytic infiltration by in vivo introduction of the IL-6 gene into keratinocytes and possibility of keratinocyte gene therapy for inflammatory skin diseases using IL-6 mutant genes. J Immunol 1998; 161:5633-9.
25. Turksen K, Kupper T, Degenstein L et al. Interleukin 6: insights to its function in skin by overexpression in transgenic mice. Proc Natl Acad Sci USA 1992; 89:5068-72.
26. Gallucci RM, Sugawara T, Yucesoy B et al. Interleukin-6 treatment augments cutaneous wound healing in immunosuppressed mice. J Interferon Cytokine Res 2001; 21:603-9.
27. Lin ZQ, Kondo T, Ishida Y et al. Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J Leukoc Biol 2003; 73:713-21.
28. Eickelberg O, Pansky A, Mussmann R et al. Transforming growth factor-beta1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts. J Biol Chem 1999; 274:12933-8.
29. Aoki H, Ohnishi H, Hama K et al. Existence of autocrine loop between interleukin-6 and transforming growth factor-beta1 in activated rat pancreatic stellate cells. J Cell Biochem 2006; 99:221-8.
30. National Institutes for Health. Guide for the Care and Use of Laboratory Animals. NIH publication no. 86-23. Bethesda, MD: NIH, 1985.
31. Gallucci RM, Sloan DK, Heck JM et al. Interleukin 6 indirectly induces keratinocyte migration. J Invest Dermatol 2004; 122:764-72.
32. Tomasek JJ, Halliday NL, Updike DL et al. Gelatinase A activation is regulated by the organization of the polymerized actin cytoskeleton. J Biol Chem 1997; 272:7482-7.
33. Song H, Wang R, Wang S et al. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005; 102:4700-5.
34. Tomasek JJ, McRae J, Owens GK et al. Regulation of alpha-smooth muscle actin expression in granulation tissue myofibroblasts is dependent on the intronic CArG element and the transforming growth factor-beta1 control element. Am J Pathol 2005; 166:1343-51.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25:402-8.
36. Tomasek JJ, Gabbiani G, Hinz B et al. Myofibroblasts and mechanoregulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3:349-63.
37. Luckett LR, Gallucci RM. Interleukin-6 (IL-6) modulates migration and matrix metalloproteinase function in dermal fibroblasts from IL-6KO mice. Br J Dermatol 2007; 156:1163-71.
38. Gallucci RM, Simeonova PP, Matheson JM et al. Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J 2000; 14:2525-31.
39. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83:835-70.
40. Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 2004; 9:283-9.
41. Heinrich PC, Behrmann I, Haan S et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374:1-20.
42. Gold LI, Sung JJ, Siebert JW et al. Type I (RI) and type II (RII) receptors for transforming growth factor-beta isoforms are expressed subsequent to transforming growth factor-beta ligands during excisional wound repair. Am J Pathol 1997; 150:209-22.
43. McCartney-Francis NL, Wahl SM. Transforming growth factor beta: a matter of life and death. J Leukoc Biol 1994; 55:401-9.
44. Martin P. Wound healing-aiming for perfect skin regeneration. Science 1997; 276:75-81.
45. Ghosh AK, Mori Y, Dowling E et al. Trichostatin A blocks TGFbeta-induced collagen gene expression in skin fibroblasts: involvement of Sp1. Biochem Biophys Res Commun 2007; 354:420-6.
46. Lijnen HR, Maquoi E, Demeulemeester D et al. Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity. Thromb Haemost 2002; 88:345-53.
47. Wang XJ, Han G, Owens P et al. Role of TGF beta-mediated inflammation in cutaneous wound healing. J Investig Dermatol Symp Proc 2006; 11:112-17.
48. Montesano R, Orci L. Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc Natl Acad Sci USA 1988; 85:4894-7.
49. Gallucci RM, Lee EG, Tomasek JJ. IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. J Invest Dermatol 2006; 126:561-8.
50. Zhang XL, Topley N, Ito T et al. Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling. J Biol Chem 2005; 280:12239-45.
51. Becker C, Fantini MC, Schramm C et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004; 21:491-501.
52. Karres I, Kremer JP, Steckholzer U et al. Transforming growth factor-beta 1 inhibits synthesis of cytokines in endotoxin-stimulated human whole blood. Arch Surg 1996; 131:1310-16; discussion 6-7.
53. Chen Y, Lu L, Wang L. [Study on gene expression of TGF beta 1 and its receptor in leukemia cells and the serum TGF beta 1 level in the patients with acute leukemia]. Zhonghua Xue Ye Xue Za Zhi 1998; 19:576-80 [In Chinese].
54. Clark RA, Ashcroft GS, Spencer MJ et al. Re-epithelialization of normal human excisional wounds is associated with a switch from alpha v beta 5 to alpha v beta 6 integrins. Br J Dermatol 1996; 135:46-51.
55. Frank S, Madlener M, Werner S. Transforming growth factors beta1, beta2, and beta3 and their receptors are differentially regulated during normal and impaired wound healing. J Biol Chem 1996; 271:10188-93.
56. Kehrl JH, Wakefield LM, Roberts AB et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986; 163:1037-50.
57. Ikeda T, Lioubin MN, Marquardt H. Human transforming growth factor type beta 2: production by a prostatic adenocarcinoma cell line, purification, and initial characterization. Biochemistry 1987; 26:2406-10.
58. Glick AB, Flanders KC, Danielpour D et al. Retinoic acid induces transforming growth factor-beta 2 in cultured keratinocytes and mouse epidermis. Cell Regul 1989; 1:87-97.
59. Kim SJ, Park K, Koeller D et al. Post-transcriptional regulation of the human transforming growth factor-beta 1 gene. J Biol Chem 1992; 267:13702-7.
60. Dudley DT, Pang L, Decker SJ et al. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995; 92:7686-9.
61. Dhandapani KM, Khan MM, Wade FM et al. Induction of transforming growth factorbeta1 by basic fibroblast growth factor in rat C6 glioma cells and astrocytes is mediated by MEK?ERK signaling and AP-1 activation. J Neurosci Res 2007; 85:1033-45.
62. Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003; 149:1-38.
63. David M, Petricoin E III, Benjamin C et al. Requirement for MAP kinase (ERK2) activity in interferon alpha-and interferon betastimulated gene expression through STAT proteins. Science 1995; 269:1721-3.
64. Chung J, Uchida E, Grammer TC et al. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997; 17: 6508-16.
65. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995; 82:241-50.
66. Zhang X, Blenis J, Li HC et al. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 1995; 267:1990-4.
67. Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene 2000; 19:2628-37.
68. Sengupta TK, Talbot ES, Scherle PA et al. Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogenactivated protein kinases. Proc Natl Acad Sci USA 1998; 95:11107-12.
69. Martinez-Salgado C, Fuentes-Calvo I, Garcia-Cenador B et al. Involvement of H-and N-Ras isoforms in transforming growth factor-beta1-induced proliferation and in collagen and fibronectin synthesis. Exp Cell Res 2006; 312:2093-106.
70. Grimm OH, Gurdon JB. Nuclear exclusion of Smad2 is a mechanism leading to loss of competence. Nat Cell Biol 2002; 4:519-22.
71. Kretzschmar M, Doody J, Timokhina I et al. A mechanism of repression of TGFbeta?Smad signaling by oncogenic Ras. Genes Dev 1999; 13:804-16.
72. Neugarten J, Medve I, Lei J et al. Estradiol suppresses mesangial cell type I collagen synthesis via activation of the MAP kinase cascade. Am J Physiol 1999; 277:F875-81.
73. Reunanen N, Foschi M, Han J et al. Activation of extracellular signal-regulated kinase 1?2 inhibits type I collagen expression by human skin fibroblasts. J Biol Chem 2000; 275:34634-9.
74. Lee SY, Lee JW, Lee H et al. Inhibitory effect of green tea extract on beta-amyloid-induced PC12 cell death by inhibition of the activation of NF-kappaB and ERK?p38 MAP kinase pathway through antioxidant mechanisms. Brain Res Mol Brain Res 2005; 140:45-54.
75. Yang LY, Ko WC, Lin CM et al. Antioxidant N-acetylcysteine blocks nerve growth factor-induced H2O2?ERK signaling in PC12 cells. Ann N Y Acad Sci 2005; 1042:325-37.
76. Arany I, Megyesi JK, Nelkin BD et al. STAT3 attenuates EGFR-mediated ERK activation and cell survival during oxidant stress in mouse proximal tubular cells. Kidney Int 2006; 70:669-74.
77. Assoian RK, Komoriya A, Meyers CA et al. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 1983; 258:7155-60.
78. Wang XP, Schunck M, Kallen KJ et al. The interleukin-6 cytokine system regulates epidermal permeability barrier homeostasis. J Invest Dermatol 2004; 123:124-31.
79. Gallucci RM, O'Dell SK, Rabe D et al. JP-8 jet fuel exposure induces inflammatory cytokines in rat skin. Int Immunopharmacol 2004; 4:1159-69.
80. Moretti S, Spallanzani A, Pinzi C et al. Fibrosis in regressing melanoma versus nonfibrosis in halo nevus upon melanocyte disappearance: could it be related to a different cytokine microenvironment? J Cutan Pathol 2007; 34:301-8.
81. Muller K, Meineke V. Radiation-induced alterations in cytokine production by skin cells. Exp Hematol 2007; 35:96-104.
82. Smith EA. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol 1992; 4:869-77.
83. Christner PJ, Jimenez SA. Animal models of systemic sclerosis: insights into systemic sclerosis pathogenesis and potential therapeutic approaches. Curr Opin Rheumatol 2004; 16:746-52.
84. Hasegawa M, Fujimoto M, Takehara K et al. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 2005; 39:1-7.
85. Matsushita T, Hasegawa M, Hamaguchi Y et al. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006; 33:275-84.